Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation (HOPE)
A Phase 1 FIH, Randomized, Double Blind, Placebo Controlled, SAD/MAD Study to Assess Safety, Tolerability, PK/PD and Food Effect of Trichomylin in Healthy Adult Participants and Preliminary Efficacy in Management of Chronic OA Pain
Sponsor: Novotech (Australia) Pty Limited
A PHASE1 clinical study on Healthy and Osteoarthritis, this trial is completed. The trial is conducted by Novotech (Australia) Pty Limited and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jul 2023 — Dec 2023 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Sep 2021 — Jul 2023 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novotech (Australia) Pty Limited
- ZYUS Life Sciences Australia Pty Ltd
- ZYUS Life Sciences Inc.
For direct contact, visit the study record on ClinicalTrials.gov .